The 3-year renal safety of a tenofovir disoproxil fumarate vs. a thymidine analogue-containing regimen in antiretroviral-naive patients

AIDS

Volumn 22, Issue 16, 2008, Pages 2155-2163

  Gallant, Joel E ^a   Winston, Jonathan A ^b   DeJesus, Edwin ^c   Pozniak, Anton L ^d   Chen, Shan Shan ^e   Cheng, Andrew K ^e   Enejosa, Jeffrey V ^e  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c ORLANDO IMMUNOLOGY CENTER   (United States)

^d CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^e GILEAD SCIENCES   (United States)

Author keywords

Kidney; Renal safety; Tenofovir disoproxil fumarate; Thymidine analogue; Treatment naive

Indexed keywords

CREATININE; EFAVIRENZ; EMTRICITABINE; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; PHOSPHORUS; STAVUDINE; TENOFOVIR DISOPROXIL;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIETARY INTAKE; DOUBLE BLIND PROCEDURE; DRUG SAFETY; FEMALE; GLOMERULUS FILTRATION RATE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KIDNEY DISEASE; KIDNEY DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; SCREENING; SIDE EFFECT; TREATMENT DURATION;

ADENINE; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CREATININE; DOUBLE-BLIND METHOD; FEMALE; GLOMERULAR FILTRATION RATE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; PHOSPHONIC ACIDS; PHOSPHORUS; PROTEINURIA; REVERSE TRANSCRIPTASE INHIBITORS; STAVUDINE; YOUNG ADULT; ZIDOVUDINE;

EID: 55249115137     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAD.0b013e3283112b8e     Document Type: Article

References (35)

1. Gallant JE, Staszewski S, Pozniak AL, DeJesus E, Suleiman J, Miller M, et al. Efficacy and safety of tenofovir DF vs. stavudine in combination therapy in antiretroviral naïve patients: a 3-year randomized trial. JAMA 2004; 292:191-201.
2. Arribas JR, Pozniak AL, Gallant JE, DeJesus E, Gazzard B, Campo RE, et al. Tenofovir disoproxil fumarate, emtricitabine, and efavirenz compared with zidovudin/lamivudine and efavirenz in treatment-naive patients: 144-week analysis. J Acquir Immune Defic Syndr 2008; 47:74-78.
3. Squires K, Pozniak AL, Pierone G, Steinhart CR, Berger D, Bellos NC, et al. Tenofovir disoproxil fumarate in nucleoside-resistant HIV-1 infection. Ann Intern Med 2003; 139 (5 Pt 1):313-321.
4. Schooley RT, Ruane P, Myers RA, Beall G, Lampiris H, Berger D, et al. Tenofovir DF in antiretroviral-experienced patients: results from a 48-week, randomized, double-blind study. AIDS 2002; 16:1257-1263.
5. Tenofovir disoproxil fumarate. In: Proceedings of the FDA Antiviral Drug Products Advisory Committee Meeting. Silver Spring, MD: US Food and Drug Administration; 2001.
6. Cihlar T, Ho ES, Lin DC, Mulato AS. Human renal organic anion transporter (hOAT1) and its role in nephrotoxicity of antiviral nucleoside analogs. Nucleos Nulceot Nucleic Acids 2001; 20:641-648.
7. Verhelst D, Monge M, Meynard JL, Fouqueray B, Mougenot B, Girard PM, et al. Fanconi syndrome and renal failure induced by tenofovir a first case report. Am J Kidney Dis 2002; 40:1331-1333.
8. Karras A, Lafaurie M, Furco A, Bourgarit A, Droz D, Sereni D, et al. Tenofovir-related nephrotoxicity in human immunodeficiency virus-infected patients: three cases of renal failure, Fanconi syndrome and nephrogenic diabetes insipidus. Clin Infect Dis 2003; 36:1070-1073.
9. Creput C, Gonzalez-Canali G, Hill G, Piketty C, Kazatchkine M, Nochy D. Renal lesions in HIV-1-positive patient treated with tenofovir. AIDS 2003; 17:935-937.
10. Rollot F, Nazal EM, Chauvelot-Moachon L, Kelaidi C, Daniel N, Saba M, et al. Tenofovir-related Fanconi syndrome with nephrogenic diabetes insipidus in a patient with acquired immunodeficiency syndrome: the role of lopinavir-ritonavir-didanosine. Clin Infect Dis 2003; 37:e174-e176.
11. Izzedine H, Hulot JS, Vittecoq D, Gallant JE, Satszewski S, Launay-Vacher V, et al. Long-term renal safety of tenofovir disoproxil fumarate in antiretroviral-naïve HIV-1-infected patients. Data from a double-blind randomized active-controlled mulitcentre study. Nephrol Dial Transplant 2005; 20:743-746.
12. Molina JM, Wilkin A, Domingo P, Myers R, Hairrell J, Naylor C, et al. Once daily vs. twice-daily lopinavir/ritonavir in antiretroviral-naïve patients: 96-week results [abstract #WePE12.3C12]. Presented at the 3rd Int'l AIDS Society Conference, July 2005.
13. Jones R, Stebbing J, Nelson M, Moyle G, Bower M, Mandalia S, Gazzard B. Renal dysfunction with tenofovir-containing highly active antiretroviral therapy regimens: a cohort and case-control study. J Acquir Immune Defic Syndr 2004; 37:1489-1495.
14. Gallant JE, Parish MA, Keruly JC, Moore RD. Changes in renal function associated with tenofovir disoproxil fumarate treatment, compared to nucleoside reverse transcriptase inhibitor treatment. Clin Infect Dis 2005; 40:1194-1197.
15. Gallant JE, Parish MA, Keruly JC, Moore RD. Tenofovir and changes in renal function: reply to Gupta [letter]. Clin Infect Dis 2005; 41:571.
16. Moore RD, Keruly JC, Gallant JE. Tenofovir and renal dysfunction in clinical practice [Poster #832]. Presented at the 14th Conference on Retroviruses and Opportunistic Infections, February 2007.
17. Young B, Buchacz K, Moorman A, Wood KC, Brooks JT, et al. Renal function in patients with preexisting renal disease receiving tenofovir-containing HAART in the HIV Outpatient Study cohort [abstract #H-382]. Presented at the 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy, September 2007.
18. US Department of Health and Human Services Panel on Clinical Practices for Treatment of HIV Infection. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. http//AIDSinfo.nih.gov. [Accessed 10th March 2008]
19. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16:31-41.
20. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann Int Med 1999; 130:461-470.
21. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification and stratification. Am J Kidney Dis 2002; 39:1-266.
22. Moreno S, Domingo P, Palacios R, Santos J, Falco V, Murillas J, et al. Renal safety of tenofovir disoproxil fumarate in HIV-1 treatment-experienced patients with adverse events related to prior NRTI use: data from a prospective, observational, multicenter study. J Acquir Immune Defic Syndr 2006; 42:385-387.
23. Winston A, Amin J, Mallon PWG, Marriott D, Carr A, Cooper D, et al. Minor changes in calculated creatinine clearance and anion-gap are associated with tenofovir disoproxil fumarate-containing highly active antiretroviral therapy. HIV Med 2006; 7:105-111.
24. Goicoechea M, Liu S, Best B, Sun S, Jain S, Kemper C, Witt M, et al. Greater tenofovir-associated renal function decline with protease inhibitor-based versus nonnucleoside reverse transcriptase inhibitor-based therapy. J Infect Dis 2008; 197:102-108.
25. Stevens L, Coresh J, Feldman H, Greene T, Lash JP, Nelson RG, et al. Evaluation of the Modification of Diet in Renal Disease study equation in a large diverse population. J Am Soc Nephrol 2007; 18:2749-2757.
26. Ravasi G, Lauriola M, Tinelli C, Brandolini M, Uglietti A, Maserati R, et al. Comparison of glomerular filtration rate estimates calculated with Cockcroft-Gault and Modification of Diet in Renal Disease equations vs creatinine clearance on 24h urine in HIV positive patients [abstract #P9.7/09]. Presented at the 11th European AIDS Conference, October 2007.
27. Vrouenraets S, Fernadez Garcia E, Wit F, Brinkman K, Hoek F, Krediet R, et al. A Comparison between different GFR-estimations and 125Iodine-iothalamate, the gold standard for GFR-measurement in HIV-infected patients on HAART [abstract #977b]. Presented at the 15th Conference on Retroviruses and Opportunistic Infections, February 2008.
28. Nelson M, Katlama C, Montaner J, Cooper D, Gazzard B, Clotet B, et al. The safety of tenofovir DF for the treatment of HIV infection in adults: the first four years. AIDS 2007; 21:1273-1281.
29. Reid A, Stöhr W, Walker S, Ssali F, Munderi P, Gilks C, on behalf of the DART Trial. Glomerular dysfunction and associated risk factors following initiation of ART in adults with HIV infection in Africa [abstract #ThAB0105]. Presented at the XVI International AIDS Conference, August 2006.
30. Gayet-Ageron A, Ananworanich J, Jupimai T, Chetchotisakd P, Prasithsirikul W, Ubolyam S, et al. No change in calculated creatinine clearance after tenofovir initiation among Thai patients. J Antimicrob Chemother 2007; 59:1034-1037.
31. Mocroft A, Kirk O, Gatell J, Reiss P, Gargalianos P, Zilmer K, et al. Chronic renal failure among HIV-1-infected patients. AIDS 2007; 21:1119-1127.
32. Wyatt CM, Winston JA, Malvestutto CV, Fishbein DA, Barash I, Cohen AJ, et al. Chronic kidney disease in HIV infection: an urban epidemic. AIDS 2007; 21:2101-2103.
33. DeJesus E, Ortiz R, Khanlou H, Voronin E, Van Lunzen J, Andrade-Villanueva J, et al. Efficacy and safety of darunavir/ritonavir versus lopinavir/ritonavir in ARV treatment-naive HIV-1-infected patients at week 48: ARTEMIS [abstract #H-718b]. Presented at the 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy, September 2007.
34. Molina JM, Andrade-Villanueva J, Echevarria J, Chetchotisakd P, Corral J, David N, et al. Efficacy and safety of once-daily atazanavir/ritonavir compared to twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine in ARV-naïve HIV-1-infected subjects: the CASTLE study, 48-week results [abstract #37]. Presented at the 15th Conference on Retroviruses and Opportunistic Infections, February 2008.
35. Walmsley S, Ruxrungtham K, Slim J, Ward D, Larson P, Raffi F. Saquinavir/r BID versus lopinavir/r BID plus emtricitabine/tenofovir QD as initial therapy in HIV-1-infected patients: the Gemini study [abstract #PS1/4]. Presented at the 11th European AIDS Conference, October 2007.